Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MediWound Ltd.
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
April 25, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 21, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
February 12, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in Two Upcoming Investor Conferences
February 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
January 09, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
December 28, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
December 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
ENLV
MDWD
MediWound to Report Third Quarter 2023 Financial Results
November 14, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
November 13, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
November 08, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
October 11, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MMM
MediWound Deploys NexoBrid® for Emergency Supply
October 09, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
September 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
September 11, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
August 15, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
August 15, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
August 15, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MDXG
MediWound to Report Second Quarter 2023 Financial Results
August 07, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Commercial Launch of NexoBrid® in Japan
August 01, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
July 10, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
July 03, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
June 14, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
May 30, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report First Quarter 2023 Financial Results
May 12, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces an Additional $10 Million Award from BARDA
May 09, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
April 26, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.